

**CURRICULUM VITAE****BIOGRAPHICAL**Name: **ROHAN GANGULI, M.D.**

Birth Date: 11 February 1950

Birth Place: India

Citizenship: United States

**Business Address:**

University of Toronto, Department of Psychiatry  
 Centre for Addiction and Mental Health (CAMH)  
 1001 Queen Street West  
 Toronto, Ontario M6J 1H4, Canada  
 Business Phone: 416-535-8501, ext 32102  
 E-Mail: rohan.ganguli@camh.ca

**Home Address:**

118S Dallas Avenue  
 Pittsburgh, PA 15208

**EDUCATION AND TRAINING****UNDERGRADUATE**

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received</i>	<i>Major Subjects</i>
9/66-6/67	St. Xavier's College Calcutta, India	Pre-University Course	<i>Biology, Physics, Chemistry</i>

**GRADUATE**

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received and Year</i>	<i>Major, Advisor and Discipline</i>
7/67-6/73	Christian Medical College and Hospital, Vellore, India M.G.R. Medical University	M.B.B.S. (Equivalent to MD) - 1973	<i>Medicine</i> Dean: A.S. Fenn, M.S. FRCS

**POST GRADUATE**

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Program Director and Discipline</i>
7/73-6/74	Christian Medical College, Vellore, India	<i>Rotating Internship</i> Dean: A.S. Fenn, M.S. FRCS
7/74-10/75	Department of Psychiatry, Christian Medical College, Vellore, India	<i>Medical Demonstrator</i> ( <i>equivalent to Psychiatric Resident</i> ), Program Director: Rose Chacko, M.D., FRCP.
11/75-6/78	Memorial University of Newfoundland Newfoundland, Canada	<i>Resident PGYI, II, III</i> Program Director: J. Hoenig, M.D.
7/78-12/78	Western Psychiatric Institute & Clinic Pittsburgh, Pennsylvania	<i>Senior Resident</i> Program Director: Peter B. Henderson, M.D.

**APPOINTMENTS AND POSITIONS****ACADEMIC**

<i>Years Inclusive</i>	<i>Name and Location of Institution</i>	<i>Rank/Title</i>
1 Jan. 1979 - 31 May 1990	Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA	Assistant Professor of Psychiatry
1 Jan. 1987 - 31 May 1990	Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA	Assistant Professor of Pathology
1 Jun. 1990 - 1 Jul. 1996	Departments of Psychiatry & Department of Pathology School of Medicine, University of Pittsburgh, Pittsburgh, PA	Associate Professor of Psychiatry and Pathology
1 Jul. 1996 - 31 Mar. 1999	Departments of Psychiatry & Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA	Professor of Psychiatry and Pathology

<b>Years Inclusive</b>	<b>Name and Location of Institution</b>	
9 Oct. 1998 - 1 Feb. 2005	Department of Psychiatry, University of Pittsburgh, School of Medicine, Pittsburgh, PA	Vice Chairman for Clinical Affairs
1 Apr. 1999 - 30 Jun. 2009	Departments of Psychiatry & Pathology, School of Medicine, Department of Health & Community Systems, School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania	Professor of Psychiatry, Pathology, and Health and Community Systems
1 Jul. 2009 - Present	Departments of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania	Adjunct Professor of Psychiatry
1 Jan. 2008 - Present	Department of Psychiatry University of Toronto	Professor of Psychiatry and Canada Research Chair
1 Jul. 2012 - Present	Dalla Lana School of Public Health, University of Toronto, Division of Social & Behavioural Health Science	Adjunct Professor

## **NON-ACADEMIC**

<b>Years Inclusive</b>	<b>Name and Location of Institution</b>	<b>Rank/Title</b>
1 Jun. 1979 - 30 Jun. 1980	Western Psychiatric Institute and Clinic, Re-socialization Treatment Center, Pittsburgh, PA	Medical Director
1 Jul. 1980 - 30 Apr. 1982	Western Psychiatric Institute and Clinic, Re-socialization Treatment Center, Pittsburgh, PA	Program Director
1 May 1982 - 31 Aug. 1982	National Institute of Mental Health and Neurosciences, Bangalore, India (Leave of Absence from University of Pittsburgh)	Assistant Professor of Psychopharmacology
1 Sept. 1982 - 31 Aug. 1983	Western Psychiatric Institute and Clinic, Depression Prevention Clinic, Pittsburgh, PA	Staff Psychiatrist

<b>Years</b> <b>Inclusive</b>	<b>Name and Location of Institution</b>	
1 Sept. 1983 - 30 Mar. 1988	Western Psychiatric Institute and Clinic, Schizophrenia Partial Hospital, Pittsburgh, PA	Medical Director
June 1986 - 30 Mar. 1988	Western Psychiatric Institute and Clinic, Schizophrenia Module, Pittsburgh, PA	Acting Medical Director
1 Apr. 1988 - 30 Jun. 1990	Western Psychiatric Institute and Clinic, Schizophrenia Module, Pittsburgh, PA	Medical Director
1 Jul. 1990 - 30 Sept. 1997	Western Psychiatric Institute and Clinic, Schizophrenia Module, Pittsburgh, PA	Medical and Research Director
1 Jul. 1997 - 8 Oct. 1998	Western Psychiatric Institute and Clinic, Comprehensive Care Division, Pittsburgh, PA	Division Chief
9 Oct. 1998 - 1 Feb. 2005	Western Psychiatric Institute and Clinic, Pittsburgh, PA	Chief of Clinical Services
1 Feb. 2005 - Feb. 2008	Services and Research for Seriously Mentally Ill	Chief of Service
Jan. 2008 - Mar. 2012	Centre for Addiction & Mental Health, Toronto Canada	Executive Vice President, Clinical Programs
April 2012 - Present	Centre for Addiction & Mental Health, Toronto, Canada	Senior Scientist

### **CERTIFICATION AND LICENSURE**

#### **SPECIALTY CERTIFICATION:**

<b>Certifying Board</b>	<b>Certification</b>	<b>Year</b>
Royal College of Physicians & Surgeons of Canada	Fellowship (F.R.C.P. [C])	1979
American Board of Psychiatry and Neurology	Diplomate	1980

**MEDICAL or OTHER PROFESSIONAL LICENSURE:**

<i>Licensing Board/State</i>	<i>License</i>	<i>Year</i>
Tamilnadu (Madras) India	Medical Licensure	1973
Commonwealth of Pennsylvania	Medical Licensure	1978
College of Physicians and Surgeons of Ontario	Medical Licensure	2008

**MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC ORGANIZATIONS**

<i>Organization</i>	<i>Year Joined</i>
Canadian Psychiatric Association	1976
American Psychiatric Association	1979
Pennsylvania Psychiatric Society	1979
Indian Psychiatric Society	1979
Indian Medical Association	1980
International Society for Neuroimmunomodulation (originally the International Working Group on Neuroimmunomodulation) *Founding member	1986
Society of Biological Psychiatry	1987
Academy of Clinical Psychiatry	1987
Society for Neuroscience	1994
Schizophrenia International Research Society	2005
International Society for Clinical Trials Methodology	2005
Canadian Public Health Association	2008
Canadian Medical Association	2009
Ontario Medical Association	2009
The Obesity Society	2011
Canadian Diabetes Association	2012

American Medical Association	2013
American Diabetes Association	2013

### **HONORS & AWARDS**

<i><b>Title of Award</b></i>	<i><b>Year Awarded</b></i>
Florence Nichols' Medical Student Prize in Psychiatry (Special prize exam in Psychiatry for undergraduate medical students)	1971
Research Scientist Development Award (NIMH)	1987
Established Investigator Award (NARSAD)	1989
Exemplary Psychiatrist Award, National Alliance for the Mentally Ill (NAMI)	1994
Golden Apple Teaching Award (University of Pittsburgh, Department of Psychiatry)	1997
Scientific Achievement Award, Indo-American Psychiatric Association (IAPA)	2000
Leadership Award, Annual Pennsylvania Forensic Rights Conference	2000
Psychiatrist of the Year, National Alliance for the Mentally Ill (NAMI)	2003
Listed in "Best Doctors in America"	1998-2006
Listed in "America's Top Doctors" (Castle & Conolley)	2000-2009
Member APA "Vision Committee"	2003
Elected to the Board of American Red Cross	2005-2009
Canada Research Chair, Canadian Institutes of Health research (CIHR)	2008
Professional of the Year, National Alliance for the Mentally Ill	2008
Pittsburgh Schizophrenia Conference Award	2009
Blue Ribbon poster: Society for Biological Psychiatry, Annual Meeting May 21 <sup>st</sup> 2010	2010
Canadian Association of Physicians of Indian Heritage Gold Medal Award	2011
President's Award Pennsylvania Community Providers' Association	2012
SCOPE International Fellow	2012

## RESEARCH

### CURRENT GRANT SUPPORT:

Canadian Diabetes Association, Operating Grant – PRINCIPAL INVESTIGATOR

2012 – 2015

Total Direct Costs: \$270,000

*Effectiveness of intensive lifestyle interventions in the management of diabetes in individuals with psychosis*

Co-Investigator(s): Gary Remington, Thomas Wolover, Enza Gucciardi

This is a randomized controlled clinical trial (RCT) evaluating a year-long intensive lifestyle intervention focused on nutrition and physical activity, in individuals who suffer from psychotic illnesses and type 2 diabetes mellitus (T2DM). One hundred and twenty individuals with psychotic illness and T2DM, who are enrolled in a primary care practice, will be randomly assigned to a weekly intervention or to gold standard diabetes education and support. The primary outcomes are change in weight and in HbA1c, over the course of 12 months.

CIHR Canada Research Chair, Tier One – Chronic Disease Management, University of Toronto

1-Feb-2008 – 31-Jan-2015

Total Direct Costs: \$1,400,000

The purpose of this Research Chair is to provide support for the chair-holder's research program investigating the causes and amelioration of factors which increase the risk of diabetes and heart disease in populations of individuals suffering from serious mental illnesses. Funds are provided for research activities as well as for the support of research trainees.

### PAST GRANT SUPPORT:

Ontario Mental Health Foundation, OMHF Research Grant Project – CO-INVESTIGATOR

2011 – 2013

Total Direct Costs: \$149,791

*Examining the effectiveness of cognitive remediation for persons with psychosis in a supported education setting*

Co-Investigator(s): Sean Kidd

This study will examine the “real world” benefits of cognitive remediation for young individuals with psychotic illness, who are supported education programs. The design is quasi experimental and is carried out in collaboration with George Brown University.

Public Health Agency of Canada, Canadian Diabetes Strategy – PRINCIPAL INVESTIGATOR

2011 – 2013

Total Direct Costs: \$200,000

*Enhancing self-management skills for persons with serious mental illness and diabetes:  
Developing a wellness-promoting intervention for residents in community housing*

The proposed project will attempt to identify specific facilitators and barriers to successful implementation and maintenance of a lifestyle intervention (LI) program that promotes healthy eating and physical activity

in Homes for Special Care (HSC) and; measure, through health outcomes, LI effectiveness. The project team will address research questions by focusing on both staff and resident issues encountered before and after the implementation of the lifestyle intervention through team-oriented, focus-group discussions with staff and feedback from residents. Running parallel to the implementation component will be a health outcomes phase examining the impact of the LI on resident health (e.g., improved glycemic control, reduction of risk factors), quality of life and satisfaction with the LI.

**NIMH – PRINCIPAL INVESTIGATOR**

**1-May-2004 – 31-Apr-2010**  
**Total Direct Costs: \$2,469,663**

***A Clinical Trial of Weight Reduction in Schizophrenia***

This is an application to conduct a clinical trial of a novel behavioral treatment for weight reduction in schizophrenia. The aim of the study is to determine the effectiveness of a behavioral intervention designed by us for weight reduction in persons suffering from schizophrenia. The effectiveness of booster session will also be tested for maintenance of weight loss. Three hundred overweight or obese patients will be randomly assigned to a behavioral weight reduction regimen or to social skills training, or usual care. Subjects who succeed in losing at least 4% of their initial body weight will be re-randomized to either booster sessions for two years or to usual care for the same period of time.

**Bristol Myers Squibb – CO-INVESTIGATOR**

**1-Jul-2006 – 30-Jun-2008**  
**Sub-Contract: \$195,000**

**(Principal Investigator: Harold Pincus, M.D.)**

***Assessing Quality Care in Veterans with Serious Mental Illness***

Independently assess how well the VA is accomplishing goals and objectives in providing treatment veterans suffering from Schizophrenia, Bipolar Disorder, Major Depression, and PTSD. Assess needs & requirements of veterans to ensure future benefits are aligned with changing needs & expectations. Assess adequacy of outcomes & measures to determine if programs are achieving intended purposes & goals.

**NIMH – CO-DIRECTOR CLINICAL CORE**

**1-Apr-1990 – 30-Jun-2008**

**(Principal Investigator: David Lewis, M.D.)**

**Centre for the Neuroscience of Mental Disorders**

***Cortical Circuitry and Cognition and Schizophrenia***

The Conte Center for the Neuroscience of Mental Disorders posits that understanding the neurobiology of schizophrenia requires a focus on the abnormalities in cognitive processing that are present in this disorder, on the components of the dorsolateral prefrontal cortex (DLPFC) and its extrinsic connections that are likely to mediate these processes, and on the developmental events that may make these neural systems vulnerable in schizophrenia.

The Clinical Services Core (Co-Director, R. Ganguli, M.D.) of the CNMD represents a unique resource that is organized around the recruitment and characterization of unmedicated schizophrenic subjects at both early and later phases of the illness. Such subjects represent an extremely limited patient population. The Core integrates and coordinates the recruitment and assessment of subjects for imaging projects in the CNMD and other currently funded collaborating investigators, which share these subjects efficiently and productively.



**NIMH – CO-INVESTIGATOR**

**1-Sep-2002 – 1-Aug-2009**  
**Total Direct Costs: \$1,959,064**

**(Principal Investigator: V.L. Nimgaonkar, M.D.)**  
***Training program for psychiatric genetics in India***

This grant will provide psychiatrists in India with basic, clinical and epidemiologic training in order to conduct psychiatric genetic studies in their home country.

**NIMH – CO-INVESTIGATOR**

**1-Sep-2002 – 31-Aug-2007**  
**Total Direct Costs: \$2,432,81**

**(Principal Investigator: V.L. Nimgaonkar, M.D.)**  
***Genetic Susceptibility in Schizophrenia***

This research project is a Multi-Institutional Collaborative Research Project (MICRP) is designed to identify regions of the human genome involved in susceptibility to schizophrenia.

**Bristol Myers Squibb – CO-PRINCIPAL INVESTIGATOR**

**30-Sep-2006 – 29-Sep-2007**  
**Sub-Contract: \$20,498**

**(Principal Investigator: Kim Coley, Ph.D.)**

The goal of this study is the identification of patient and treatment factors that predict successful treatment with aripiprazole. diagnoses and age cohorts.

**Stanley Research Foundation – PRINCIPAL INVESTIGATOR**

**1-May-2004 – 31-Apr-2007**  
**Total Direct Costs: \$276,750**

***Randomized clinical trial of augmentation with atomoxetine for the treatment of negative symptoms***

The aim of this double-blind, randomized parallel group, clinical trial is to examine the effect of atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI) on negative symptoms and quality of life, in persons suffering from schizophrenia.

**NIMH – CO-INVESTIGATOR**

**24-Jul-2001 – 30-Jun-2006**  
**Total Direct Costs: \$1,871,390**

**(Principal Investigator: V.L. Nimgaonkar, M.D.)**  
***Neurobehavioral Family Study of Schizophrenia***

The goal of this study is to combine genetic and neurobiologic paradigms enabling detection and localization of genes that modulate susceptibility to schizophrenia and related phenotypes.

**NIMH – CO-INVESTIGATOR**

**1-Dec-2001 – 30-Nov-2004**  
**Total Direct Costs: \$1,065,651**

**(Principal Investigator: A. Rotondi)**

***Schizophrenia Patient and Family Continuity of Care***

The overall goal of this project is to assess the feasibility of using the World Wide Web to help provide patients suffering from schizophrenia, and their families, with a comprehensive, long-term psychoeducation program.

**JANSSEN RESEARCH FOUNDATION – PRINCIPAL INVESTIGATOR**

**12-Mar-2001 – 31-Jan-2003**  
**Total Direct Costs: 517,990**

**RIS-USA-T205**

**LILLY ENDOWMENT INC. – PRINCIPAL INVESTIGATOR**

**Total Direct Costs: \$128,476**

***The Effectiveness of Behavioral Interventions for Prevention of Weight Gain in Mentally Ill Patients***

**GRANTS WHICH ENDED PRIOR TO 2003:**

Autoimmune Phenomena and Psychotic Relapse in Schizophrenia". NIMH RO1: MH41883-01 (07/01/86-08/31/94). Principal Investigator.

"Immune Mechanisms in Schizophrenia". NIMH K-2:MH00710 (Research Scientist Development Award, RSDA) (09/01/1987-08/30/1992). Principal Investigator.

"Biology of Schizophrenia and Mood Disorders in Families". NIMH: MH43687 (9/1/87 - 8/31/88). Co-Principal Investigator (M.S. Keshavan, M.D., P.I.).

"Clozaril in Treatment Resistant Patients". Sandoz Pharmaceuticals Corporation (12/18/88 - 6/30/89). Principal Investigator.

"EEG Sleep and Heterogeneity in Schizophrenia". NIMH MH 45203-02 (04/01/91-03/31/95). Co-Principal Investigator.

"Clozapine Treatment Response and Disability". NIMH MH 46672-01A2 (04/01/92-03/31/94). Co-Principal Investigator.

"Dose-Response Study in the Treatment of Negative Symptoms of Schizophrenia with Pramipexole." Upjohn Pharmaceuticals M/2730/0050 (12/01/94 - 1/15/97) Principal Investigator.

"PET Studies of Neurotransmitter Interactions in Humans" 2 R01 MH49936-04A1, NIMH. **CO INVESTIGATOR** (P.I. Gwen Smith, Ph.D.) 6/1/1997 - 10/31/2000

New Antipsychotics--Clinical Trials and Followup 3 RO1 MH46672, NIMH. **CO-PRINCIPAL INVESTIGATOR** (P.I. KNR Chengappa, M.D.) 4/01/1995-08/31/2000

"Medication Software for Mental Patients." NIMH 2 R44 MH47615 (5/1/95-3/31/98) Co-Principal Investigator

“Behavioral Neuroscience and Schizophrenia” (Clinical Core) NIMH 07/1/96 - 06/30/01 Co-Investigator (P.I. David Lewis)

“Treatment of tardive dyskinesia in schizophrenic patients with olanzapine” F1D-US-HGH (10/01/1998 - 9/30/2000) Lilly Endowment Inc. Principal Investigator.

“A Randomized Trial to Assess the Outcomes and Costs of Risperdal vs Conventional Therapy in Schizophrenia.” RIS-USA-56 (3/1/95-12/31/98) Principal Investigator.

“Strategies for Switching from conventional Antipsychotics to Olanzapine.” Eli Lilly Pharmaceutical (6/1/97-11/30/98) Principal Investigator.

“Incidence of Tardive Dyskinesia in Elderly Patients Treated with Olanzapine.” F1D-US-HGGE (1/1/98-5/1/99) Principal Investigator.

“Retrospective Study to Examine the Effect of Risperidone on the Indications for Clozapine.” Novartis Pharmaceutical 8/1/97-5/31/99. Principal Investigator.

Cost-Effectiveness and Functional Outcomes of Olanzapine in the Treatment of Schizophrenia in Usual Clinical Practice: A Randomized Clinical Study (Covance) 5/1/1998 - 4/30/2001 Principal Investigator.

Risperidone depot (microspheres) vs. Placebo in the treatment of subjects with schizophrenia. RIS-USA-121/196 03/01/2000-06/01/2002 (Janssen R

### **GRANT REVIEWING ACTIVITIES:**

Reviewer NIMH Special Emphasis Panel 2013, 2014

Reviewer NIMH Interventions Committee for Adult Disorders (ITVA) October 17<sup>th</sup> 2012

### **PAST GRANT REVIEWING ACTIVITIES:**

Permanent Member NIMH Interventions Committee for Schizophrenia Spectrum Disorders, Personality Disorders, and Disorders of Late Life (ITSP) 2004-2008

NIMH Data and Safety Monitoring Board (DSMB), 2004 – 2008 (Chair 2005-2006)

Reviewer, Foundation for the National Institutes of Health (FNIH) – 2005- 2006

Ad hoc Member NIMH Study Section – various 2005-2007

Reviewer NIMH Loan Repayment Program (LRP) – 2005 - 2007

Ad hoc grant reviewer VA Merit reviews, 1988 – present

External reviewer Canadian Institutes for Health Research (formerly known as the Medical research Council of Canada), 1989 – 2008

## PUBLICATIONS (\*=Senior author)

- 1 Mellor, C.S., & **Ganguli, R.** (1979). Semiography of tremor in alcohol withdrawal. In: M. Galanter (Ed.), *Currents in Alcoholism (Vol. 5, 207-212)*. New York: Grune & Stratton. PMID 755622
- 2 **Ganguli, R.** (1980). Review of *Experimental Design in Psychiatry: Research Methods for Clinical Practice*. *Canadian Journal of Psychiatry, 29*, 67-68.
- 3 **Ganguli, R.** & Detre, T.P. (1981). Psychopharmacology and behavior therapy. In L. Michelson, M. Hersen & S.M. Turner (Eds.) *Future perspectives in behavior therapy*. New York: Plenum Press. 1981.
- 4 **Ganguli, R.** (1983). Medical assessment. In M. Hersen, A.E. Kazdin & A.S. Bellack (Eds.), *Clinical psychology handbook*. New York: Pergamon Press.
- 5 **Ganguli, R.** (1983). The rational use of psychotropic drugs. *Urban Health, 12*, 42-48.
- 6 **Ganguli, R.** (1985). Medical aspects. In M. Hersen (Ed.), *Practice of inpatient behavior therapy: Clinical guide*. New York: Grune & Stratton Inc.
- 7 **Ganguli, R.** & Rabin, B.S. (1985). Lymphocyte sensitivity to glucocorticoids. *American Journal of Psychiatry, 142*, 989-990. PMID 4025603
- 8 **Ganguli, R.** & Raghur, U. (1985). Tardive Dyskinesia, impaired recall and informed consent. *Journal of Clinical Psychiatry, 46*, 434-435. PMID 2864333
- 9 Mezzich, J.E., Dow, J.T., **Ganguli, R.**, Munetz, M., & Segal, M. (1986). Computerized initial and discharge evaluations. In J.E. Mezzich (Ed.), *Clinical Care and Information Systems in Psychiatry* Washington, DC: American Psychiatric Press.
- 10 **Ganguli, R.**, Rabin, B.S., & Jarrett, D. (1987). Cortisol and dexamethasone blood levels and phytohemagglutinin response. *American Journal of Psychiatry, 144*, 524. PMID 3565627
- 11 **Ganguli, R.**, Rabin, B.S., Kelly, R.H., Lyte, M., & Ragu, U. (1987). Clinical and laboratory evidence of autoimmunity in acute schizophrenia. *Annals of the New York Academy of Sciences, 496*, 676-85.
- 12 **Ganguli, R.**, Rabin, B.S., Raghur, U., & Ulrich, R. (1987). Lymphocyte subpopulations in schizophrenics and normals and the effects of varying antipsychotic dosage. In E. Kurstak, J.Z. Lipowski & P.V. Morolov (Eds.), *Viruses, immunity and mental illness*. New York: Plenum Press
- 13 **Ganguli, R.**, Reynolds, .CF., & Kupfer ,D.J. (1987). EEG sleep in young never-medicated, schizophrenic patients: A comparison with delusional and non-delusional depressives and with healthy controls. *Archives of General Psychiatry, 44*, 36-44. PMID 3800582
- 14 Kelly, R.H., **Ganguli, R.**, & Rabin, B.S. (1987). Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. *Biological Psychiatry, 22*, 1488-1490. PMID 3676378
- 15 **Ganguli, R.**, Kelly, R.H., & Rabin, B.S. (1988). Autoimmunity as a factor in the pathogenesis of schizophrenia. *Clinical Immunology Newsletter, 9*, 74-76.
- 16 Rabin, B.S., **Ganguli, R.**, Cunnick, J.E., & Lysle, D. (1988). The central nervous system – immune system relationship. *Clinics in Laboratory Medicine, 8*, 253-268. PMID 3284696

- 17 **Ganguli, R.,** & Rabin, B.S. (1989). Differences in interleukin-2 production in blacks and whites. *New England Journal of Medicine*, 320(6), 399
- 18 **Ganguli, R.,** & Rabin, B.S. (1989). Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. *Archives of General Psychiatry*, 46(3), 292.
- 19 **Ganguli, R.,** Rabin, B.S., & Belle, S.H. (1989). Decreased Interleukin-2 production in schizophrenic patients. *Biological Psychiatry*, 26, 427-430. doi: 0006-3223(89)90061-9 [pii] PMID 2788463
- 20 **Ganguli, R.,** Rabin, B.S., & Kelly, R.H. (1989). Multiple autoantibodies and autoimmune disease in schizophrenic patients: Evidence for an autoimmune pathogenesis. In J. Hadden, K. Masek & G. Nistico (Eds.), *Interactions among CNS, neuroendocrine and immune systems*. Rome: Pythagora Press.
- 21 Keshavan, M. S., Brar, J., **Ganguli, R.,** & Jarrett, D. (1989). DST and schizophrenic symptomatology. *Biological Psychiatry*, 26(8), 856-8.
- 22 Rabin, B.S., Cohen, S., **Ganguli, R.,** Lysle, D.T., & Cunnick, J.E. (1989). Bidirectional interaction between the central nervous system and the immune system. *Critical reviews in immunology*, 9, 279-312. PMID 2679662
- 23 Keshavan, M.S., & **Ganguli, R.** (1990). The biology of schizophrenia. In R. Pohl & S. Gershon (Eds.), *The biological basis of psychiatric treatment*. Basel: S. Karger and Co.
- 24 Rabin, B.S., **Ganguli, R.,** Lysle, D.T., & Cunnick, J.E. (1990). Interaction between the brain and the immune system [Review]. *Immunology Series*, 52, 125-54. PMID 2091777
- 25 Rabin, B.S., **Ganguli, R.,** Lysle, D., & Cunnick, T. (1990). Interaction between the central nervous system and the immune system. In P.E. Bigazzi, G. Wick & K. Wicher (Eds.), *Progress in Autoimmunity*. New York: Marcel Dekker, Inc.
- 26 Chengappa, K.N.R., Cochran, J., Rabin, B.S., & **Ganguli, R.\*** (1991). Handedness and Autoantibodies. *Lancet*, 338, 694. doi: 0140-6736(91)91268-Y [pii] PMID 1679491
- 27 Chengappa, K.N.R., Nimgaonkar, V.L., & **Ganguli, R.** (1991). Immunological alterations. In M.S. Keshavan & G. Kennedy (Eds.), *Drug Induced Dysfunction in Psychiatry* (311-324). New York: Hemisphere Publications.
- 28 Chengappa, R., Carpenter, A.B., Keshavan, M.S., Yang, Z.W., Kelly, R.H., Rabin, B.S., & **Ganguli, R.\*** (1991). Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and never-medicated schizophrenic patients. *Biological Psychiatry*, 30, 731-735. PMID 1683585
- 29 Kapur, S., **Ganguli, R.,** Ulrich, R., & Raghu, U. (1991). Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. *Schizophrenia Research*, 6, 49-54. doi: 0920-9964(91)90020-R [pii] PMID 1686184
- 30 Keshavan, M.S., Reynolds, C.F., **Ganguli, R.,** Brar, J.S., & Houck, P. (1991). Electroencephalographic sleep and cerebral morphology in functional psychoses: A preliminary study with computed tomography. *Psychiatry Research*, 39, 293-301. PMID 1798827
- 31 Keshavan, M.S., Reynolds, C.F., Houck, P., & **Ganguli, R.** (1991). Reduced REM latency in

schizophrenia: Pathophysiological mechanisms. In G. Racagni, N. Brunello & T. Fukuda (Eds.), *Biological Psychiatry* Amsterdam: Excerpta Medica.

- 32 Birmaher, B., Baker, R., Kapur, S., Quintana, H., & **Ganguli, R\***. (1992). Clozapine for the treatment of adolescents with schizophrenia. *Journal of the American Academy of Child and Adolescent Psychiatry*, *31*, 160-164. doi: S0890-8567(09)64420-8 [pii] 10.1097/00004583-199201000-00024 PMID 1537770
- 33 Chengappa, K.N.R., Carpenter, A.B., Yang, Z.W., Brar, J.S., Rabin, B.S., & **Ganguli, R\***. (1992). Elevated IgG antihistone antibodies in a subgroup of medicated schizophrenic patients. *Schizophrenia Research*, *7*, 49-54. PMID 1350460
- 34 Chengappa, K.N.R, **Ganguli, R.**, Ulrich, R., Rabin, B.S., Cochran, J., Brar, J.S., Yang, Z.W., & DeLeo, M. (1992). The prevalence of autoantibodies among right and left handed schizophrenic patients and control subjects. *Biological Psychiatry*, *32*, 803-811. doi: 0006-3223(92)90083-C [pii] PMID 1450294
- 35 Chengappa, K.N.R., **Ganguli, R.**, Yang, Z.W., Brar J.S., Li, L., & Rabin, B.S. (1992). Left-handed first-episode, neuroleptic-naive schizophrenic patients have a higher prevalence of autoantibodies. *Schizophrenia Research*, *8*, 75-80. doi: 0920-9964(92)90063-B [pii] PMID 1419935
- 36 Chengappa, K.N.R., **Ganguli, R.**, Yang, Z.W., Shurin, G., Cochran, J., Brar, J.S., & Rabin, B.S. (1992). Non-right sidedness: An association with lower IL-2 production. *Life Sciences*, *51*, 1843-1849. PMID 1447950
- 37 **Ganguli, R.**, & Brar, J.S. (1992). Generalizability of first episode studies in schizophrenia. *Schizophrenia Bulletin*, *18*. PMID 1411333
- 38 **Ganguli, R.**, Brar, J.S., & Rabin, B.S. (1992). Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. *Biological Psychiatry*, *32*, 228-231, 1992. doi: 0006-3223(92)90306-K [pii] PMID 1457630
- 39 **Ganguli, R.**, Brar, J.S., Solomon, W., Chengappa, K.N.R., & Rabin, B.S. (1992). Altered IL-2 production in schizophrenia: Association between clinical state and autoantibody production. *Psychiatry Research*, *44*, 113-123. PMID 1480677
- 40 Levin, H., Chengappa, K.N.R., Kambhampati, R.K., Madhavi, N., & **Ganguli, R\***. (1992). Should chronic treatment refractory akathisia be an indication for the use of Clozapine in schizophrenic patients? *Journal of Clinical Psychiatry*, *53*, 248-251. PMID 1353492
- 41 Nimgaonkar, V.L., **Ganguli, R.**, Washington, S.S., & Chakravarti., A. (1992). Schizophrenia and porphobilinogen deaminase gene polymorphisms: An association study. *Schizophrenia Research*, *8*, 51-58. doi: 0920-9964(92)90060-I [pii] PMID 1358185
- 42 **Ganguli, R.**, Brar, J.S., Chengappa, K.N.R., Nimgaonkar, V.L., Yang, Z.W., & Rabin, B.S. (1993). Autoimmunity in schizophrenia: A review of recent findings. *Annals of Medicine*, *25*, 489-496. PMID 8251150

- 43 **Ganguli, R.**, & Rabin, B.S. (1993). CD5 positive B lymphocytes in schizophrenia: No alteration in numbers or percentage as compared to controls. *Psychiatry Research*, *48*, 69-78. PMID 7692460
- 44 Nimgaonkar, V.L., **Ganguli, R.**, Rudert, W.A., Vavassori, C., Rabin, B.S., & Trucco, M. (1993). A negative association of schizophrenia with an allele of the HLA DQB1 gene among African-Americans. *Schizophrenia Research*, *8*, 199-209. PMID 8435383
- 45 Nimgaonkar, V.L., Scott, J.A., Brar, J.S., **Ganguli, R.**, & Chakravarti, A. (1993). Cooccurrence of schizophrenia and Treacher Collins Syndrome. *American Journal of Medical Genetics*, *48*, 156-158. doi: 10.1002/ajmg.1320480308 PMID 8291570
- 46 Nimgaonkar, V.L., Zhang, X.R., Caldwell, J.G., **Ganguli, R.**, & Chakravarti, A. (1993). Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: probable effects of family history of schizophrenia. *American Journal of Medical Genetics*, *48*, 214-7. doi: 10.1002/ajmg.1320480408 PMID 8135304
- 47 Chengappa, K.N.R., **Ganguli, R.**, Yang, Z.W., Shurin, G., Brar, J.S., Rosenbleet, J.A., & Rabin, B.S. (1994). Differences in serum interleukin-6 (IL-6) between healthy dextral. and non-dextral subjects. *Neuroscience Research*, *20*, 185-188. PMID 7808701
- 48 **Ganguli, R.**, Brar, J.S., Damaraju, C.V., Gubbi, A.V., Yang, Z.W., Chengappa, K.N.R., & Rabin, B.S. (1994). Clinical correlates of immune dysfunction in a subgroup of schizophrenic patients. In A. Beigel, J.J. LopezIbor, J.A. Costa & E. Silva E (Eds.), *Past, Present and Future of Psychiatry*. River Edge, NJ: World Scientific.
- 49 **Ganguli, R.**, Brar, J.S., & Rabin, B.S. (1994). Immune abnormalities in schizophrenia: Evidence for the autoimmune hypothesis. *Harvard Review of Psychiatry*, *2*, 70-83. PMID 9384885
- 50 **Ganguli, R.**, Mintun, M.A., Becker, J.T., Brar, J.S., Diehl, D., DeLeo, M., Madoff, D., & Martids, A. (1994). Effects of hydrocortisone infusion on rCBF in schizophrenic patients during a memory task: an O<sup>15</sup> PET study. *Annals of the New York Academy of Sciences*, *746*, 385-387. PMID 7825893
- 51 **Ganguli, R.**, Yang, Z., & Shurin, G. (1994). Concentracion serica de interleucina-6 en la esquizofrenia: Aumento asociado a la duracion de la enfermedad. *Focus on Psychiatry*, *2*(3), 67-68.
- 52 **Ganguli, R.**, Yang, Z.W., Shurin, G., Chengappa, K.N.R, Brar, J.S., Gubbi, A.V., & Rabin, B.S. (1994). Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. *Psychiatry Research*, *51*, 1-10. PMID 7910974
- 53 Silver, A.S., Yang, Z.W., **Ganguli, R.**, & Nimgaonkar, V.L. (1994). An inhibitory effect of psychoactive drugs on a human neuroblastoma cell line. *Biological Psychiatry*, *35*, 824-826. PMID 7913837
- 54 Yang, Z.W., Chengappa, K.N.R, Shurin, G., Brar, J.S., Rabin, B.S., Gubbi, A.V., & **Ganguli, R\***. (1994). An association between antihippocampal antibody level and lymphocyte production of IL-2 in patients with schizophrenia. *Psychological Medicine*, *24*, 449-455. PMID 8084939
- 55 Carter, C.S., Mulsant, B.H., Sweet, R., Maxwell, R, Coley, K., **Ganguli, R.**, & Branch, R. (1995). Risperidone use in a teaching hospital during its first year after market approval: Economic and clinical implications. *Psychopharmacology Bulletin*, *31*, 719-725. PMID 8851645

- 56 Chengappa, K.N.R., **Ganguli, R.**, Yang, Z.W., Shurin, G., Brar, J.S., & Rabin, B.S. (1995). Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. *Biological Psychiatry*, *37*, 546-549. doi: 0006-3223(94)00363-8 [pii] 10.1016/0006-3223(94)00363-8 PMID 7619978
- 57 Chengappa, K.N.R., Nimgaonkar, V.L., Bachert, C., Yang, Z.W., Rabin, B.S., & **Ganguli, R\***. (1995). Obstetric complications and autoantibodies in schizophrenia. *Acta Psychiatrica Scandinavica*, *92*, 270-273. PMID 8848952
- 58 **Ganguli, R.**, Brar, J.S., Chengappa, K.N.R., DeLeo, M., Yang, Z.W., Shuri,n G., & Rabin, B.S. (1995). Mitogen-stimulated IL-2 production in never-medicated, first episode schizophrenic patients: The influence of age of onset and negative symptoms. *Archives of General Psychiatry*, *52*, 668-672. PMID 7632120
- 59 **Ganguli, R.**, Brar, J.S., & Rabin, B.S. (1995). Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors [In reply]. *Archives of General Psychiatry*, *52*(11), 877-878.
- 60 Keshavan, M.S., Miewald, J., Haas, G., Sweeney, J., **Ganguli, R.**, & Reynolds, C.F. (1995). Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders. *Journal of Psychiatric Research*, *29*, 303-314. doi: 0022-3956(95)00023-X [pii] PMID 8847657
- 61 Nimgaonkar, V.L., & **Ganguli, R.** (1995). Association study of schizophrenia and the IL-2 receptor B chain gene. *Neuropsychiatric Genetics*, *60*, 448-451. doi: 10.1002/ajmg.1320600517 PMID 8546160
- 62 Nimgaonkar, V.L., Sanders, A.R., **Ganguli, R.**, Zhang, X.R., Brar, J.S., Hogge, W., Fann, W.E., Patel, P.I., & Chakravarti, A. (1996). Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples. *American Journal of Medical Genetics*, *67*, 505-14. doi: 10.1002/(SICI)1096-8628(19961122)67:6<505::AID-AJMG1>3.0.CO;2-G [pii] 10.1002/(SICI)1096-8628(19961122)67:6<505::AID-AJMG1>3.0.CO;2-G PMID 8950407
- 63 Nimgaonkar, V.L., Zhang, X.R., Brar, J.S., DeLeo, M., & **Ganguli, R.** (1995). Lack of association of schizophrenia with the neurotrophin-3 gene. *Acta Psychiatrica Scandinavica*, *92*, 464-466. PMID 8837975
- 64 Tanner, T.B., **Ganguli, R.**, Reddy, R., Allen, M., & Field, K. (1995). Risperidone for treatment-refractory schizophrenia [Letter]. *American Journal of Psychiatry*, *152*(8), 1223. PMID 7542836
- 65 Tanner, T.B., Gitlow, S., **Ganguli, R.**, Kubacka, R., Bulsant, B.H., & Epstein, B.A. (1995). Developing a Medication Information Workstation for Patients. In K. Morgan, R.M. Satava, H.B. Sieburg, R. Mattheus, & J.P. Christensen (Eds.), *Interactive Technology and the New Paradigm for Healthcare*. Amsterdam: IOS Press & Ohmsha.
- 66 Nimgaonkar, V.L., Zhang, X.R., Brar, J.S., DeLeo, M., & **Ganguli, R.** (1996). 5-HT<sub>2</sub> receptor gene locus: association with schizophrenia or treatment response not detected. *Psychiatric Genetics*, *6*, 23-7. PMID 8925254
- 67 Brar, J.S., Chengappa, K.N.R., Parepally, H., Sandman, A.R., Kreinbrook, S.B., Sheth, S.A., & **Ganguli, R\***. (1997). The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. *Annals of Clinical Psychiatry*, *9*, 227-234. PMID 9511946
- 68 **Ganguli, R.** (1997). Cytokine abnormalities in schizophrenia: A review of their pathogenic



significance, with particular reference to the autoimmune hypothesis. In G. Wieselmann (Ed.), *Current Update in Psychoimmunology - Key Topics in Brain Research*. New York: SpringerWienNewYork.

- 69 **Ganguli, R.,** & Brar, J.S. (1997). Smoking affects plasma soluble IL-2 receptors in schizophrenic patients (in reply). *Archives of General Psychiatry*, *54*, 89.
- 70 **Ganguli, R.,** Carter, C.S., Mintun, M., Brar, J.S., Becker, J.T., Sarma, R, Nichols, T., & Bennington, E. (1997). A PET brain mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia. *Biological Psychiatry*, *41*, 33-42. doi: S0006322396002065 [pii] PMID 8988793
- 71 **Ganguli, R.,** & Gubbi, A. (1997). Clinical and immunological characteristics of a subgroup of patients suffering from schizophrenia. In A.E. Henneberg & W.P. Kaschka (Eds.), *Advances in Biological Psychiatry: Vol. 18. Immunological Alterations in Psychiatric Diseases*. (35-43). Basel, Switzerland: Karger. doi: 10.1159/000058633
- 72 Nimgaonkar, V.L., Rudert, W.A., Zhang, X., Trucco, M., & **Ganguli, R.** (1997). Negative association of schizophrenia with HLA DQB1\*0602: Evidence from a second African-American cohort. *Schizophrenia Research*, *23*, 81-86. doi: S0920-9964(96)00086-2 [pii] 10.1016/S0920-9964(96)00086-2 PMID 9050131
- 73 Nimgaonkar, V.L., Ward, S.E., Agarde, H., Weston, N., & **Ganguli, R.** (1997). Fertility in schizophrenia: results from a contemporary US cohort. *Acta Psychiatrica Scandinavica*, *94*, 1-6. PMID 9197899
- 74 Nimgaonkar, V.L., Zhang, X.R., Brar, J.S., DeLeo, M., & **Ganguli, R.** (1997). 5-HT<sub>2</sub> receptor gene locus: Association with schizophrenia or treatment response not detected. *Psychiatric Genetics*, *6*, 23-27. PMID 00041444-199621000-00005
- 75 Carter, C.S., Perlstein W.M., **Ganguli, R.,** Brar, J.S., Mintun, M., & Cohen, J.D. (1998). Functional Hypofrontality and Working Memory Dysfunction in Schizophrenia. *American Journal of Psychiatry*, *155*, 1285-87. PMID 9734557
- 76 Chandy, K.G., Fantino, E., Wittekindt, O., Kalman, K., Tong, L.L., Ho, T.H., Gutman G.A., Crocq, M.A., **Ganguli, R.** (...) D.J., Gargus, J.J. (1998). Isolation of a novel potassium channel gene hSDCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? *Molecular Psychiatry*, *3*, 32-7. PMID 9491810
- 77 **Ganguli, R.,** & Brar, J.S. (1998). The effects of risperidone and olanzapine on the indications for clozapine. *Psychopharmacology Bulletin*, *34*, 83-87. PMID 9564203
- 78 **Ganguli, R.,** Brar, J.S., Vemulapalli, H., Jafar, H., Ahuja, R., Sharma, .S, & Wirth, R.J. (1998). Mini-Mental State Examination (MMSE) performance of partially remitted community-dwelling patients with schizophrenia. *Schizophrenia Research*, *33*, 45-52. doi: S0920-9964(98)00044-9 [pii] PMID 9783343
- 79 Rao, D., Jonsson, E.G., Paus, S., **Ganguli, R.,** Nothen, M., & Nimgaonkar, V.L. (1998). Schizophrenia and the serotonin transporter gene. *Psychiatric Genetics*, *8*, 207-12. PMID 9861638
- 80 **Ganguli, R.** (1999). Weight Gain Associated with Antipsychotic Drugs. *Journal of Clinical Psychiatry*, *21*, 20-24. PMID 10548138

- 81 McLennan, J., & **Ganguli, R\***. (1999). Family planning and parenthood needs of women with severe mental illness: Clinicians' perspective. *Community Mental Health Journal*, 35, 369-380. PMID 10452703
- 82 Strauss, J., Xhang, X.R., Barron, Y., **Ganguli, R.**, & Nimgaonkar, V.L. (1999). Lack of association between schizophrenia and a pancreatic phospholipase A-2 gene (PLA2G1B) polymorphism. *Psychiatric Genetics*, 9, 1-3. PMID 10551547
- 83 Chowdari, K.V., Wood, ., **Ganguli, R.**, Gottesman, I., & Nimgaonkar, V.L. (2000). Lack of association between schizophrenia and a CAG repeat polymorphism of the hSKCa3 gene in a North Eastern US sample. *Molecular Psychiatry*, 5, 237-238. PMID 10889524
- 84 Wright, P., Nimgaonkar, V., **Ganguli, R.**, & Murray, R.M. (2000). *HLA and Psychiatric Disease in HLA & Human Disease* P. Wright & R. Murray, (Eds.). Academic Press.
- 85 **Ganguli, R.**, Brar, J.S., Ayrton, Z. (2001). Weight gain over four months in schizophrenia patients: A comparison of olanzapine and risperidone. *Schizophrenia Research*, 49, 261-7. doi: S0920996400000803 [pii] PMID 11356587
- 86 Kane, J.M., Marder, S.R., Schooler, N.R., Wirshing, W.C., Umbricht, D., Baker, R.W., Wirshing, D.A., Safferman, A., **Ganguli, R.** (...) Borenstein, M. (2001). Clozapine and haloperidol in moderately refractory schizophrenia: A 6-month randomized and double-blind comparison. *Archives of General Psychiatry*, 58, 965-972. doi: yoa9127 [pii] PMID 11576036
- 87 Levine, J., Chengappa, K.N.R., Pate,l A., Vagnucci, A., John, V., Brar, J.S., Chalasani, .L, Parepally, H., & **Ganguli, R\***. (2001). Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. *Journal of Psychiatric Practice*, 7, 432-439. doi: 00131746-200111000-00011 [pii] PMID 15990558
- 88 Mullen, B., Brar, J.S., Vagnucci, A.H., & **Ganguli, R\***. (2001). Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone. *Schizophrenia Research*, 48, 155-8. doi: S0920-9964(00)00061-X [pii] PMID 11345946
- 89 **Ganguli, R.** (2002). Rationale and strategies for switching antipsychotics. *American Journal of HealthSystem Pharmacies*, 59, 22-26. PMID 12455296
- 90 **Ganguli, R.**, Singh, A., Bras, J.S., Carter, C., & Mintun, M. (2002). Hydrocortisone induced regional cerebral activity changes in schizophrenia: a PET study. *Schizophrenia Research*, 56, 241-247. PMID 12072173
- 91 Aziz, H., Brar, J.S., Mullen, B., Vagnucci, A., & Ganguli, R. (2003). Treatment of diabetes at an integrated psychiatric and primary care clinic at a university mental health center: A model to follow? *Schizophrenia Research*, 60, 104-105.
- 92 Strassnig, M., Brar, J.S., & **Ganguli, R\***. (2003). Body mass index and quality of life in community-dwelling patients with schizophrenia. *Schizophrenia Research*, 62(1-2), 73-76. PMID 12765746
- 93 Strassnig, M., Brar, J.S., & **Ganguli, R\***. (2003). Nutritional assessment of patients with schizophrenia: A preliminary study. *Schizophrenia Bulletin*, 29(2), 393-397. PMID 14552512

- 94 Deshpande, S.N., Bhatia, T., Wood, J., Brar, J.S., Thelma, B.K., **Ganguli, R.** (...) Nimgaonkar, V.L. (2004). Evaluation of familial influences on the course and severity of schizophrenia among US and Indian cases. *Social Psychiatry & Psychiatric Epidemiology*, 39(5), 369-74. PMID 5133593
- 95 Brar, J.S., **Ganguli, R\***, Pandina, G., Turkoz, I., Berry, S., & Mahmoud, R. (2005). Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. *Journal of Clinical Psychiatry*, 66(2), 205-212. PMID 15705006
- 96 **Ganguli, R.**, & Brar, J.S. (2005). Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain. *Journal of Clinical Psychiatry*, 66, 951.
- 97 Rotondi, A.J., Haas, G.L., Anderson, C.M., Newhill, C.E., Spring, M.B., **Ganguli, R.**, Gardner, .B., Rosenstock, J.B., Rosenstock, J.B. (2005). A clinical trial to test the feasibility of a telehealth psychoeducational intervention for persons with schizophrenia and their families: Intervention and 3-month findings. *Rehabilitation Psychology*, 50, 325-336. doi: 10.1037/0090-5550.50.4.325
- 98 Strassnig, M., Brar, J.S., & **Ganguli, R\***. (2005). Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. *Schizophrenia Research*, 76, 343-351. PMID 15949667
- 99 Strassnig, M., Brar, J.S., & **Ganguli, R\***. (2005). Dietary intake of patients with schizophrenia. *Psychiatry*, 2, 31-35.
- 100 Strassnig, M., Brar, J.S., & **Ganguli, R\***. (2005). Self reported body weight perception and dieting practices in community dwelling patients with schizophrenia. *Schizophrenia Research*, 75, 425-432. PMID 15885533.
- 101 **Ganguli, R.** & Strassnig, M. (2006). Are older antipsychotic drugs obsolete? [Editorial]. *British Medical Journal*, 332(7554), 1346-7. PMID 16763227
- 102 Strassnig, M., Brar, J.S., & **Ganguli, R\***. (2006). Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. *Schizophrenia Research*, 86, 269-275. PMID 16859897
- 103 Eack, S., Schooler, N., & **Ganguli, R.** (2007). Gerard E. Hogarty: Combining science and humanism to improve the care of persons with schizophrenia. *Schizophrenia Bulletin*, 33(5), 1056-1062. PMID 17617662
- 104 **Ganguli, R.** (2007). Behavioral therapy for weight loss in patients with schizophrenia. *Journal of Clinical Psychiatry*, 68(Suppl. 4), 19-25. PMID 17539696.
- 105 **Ganguli, R.**, Vreeland, B., & Newcomer, J.W. (2007). Monitoring and managing weight gain in the mentally ill. *Journal of Clinical Psychiatry*, 68(6), e14. PMID 17592901.
- 106 Rotondi, A.J., Sinkule Haas, G., Spring, M.B., Litschge, C.M., Newhill, C., **Ganguli, R.**, & Anderson, C.M. (2007). Designing websites for persons with cognitive deficits: Design and usability of a psychoeducational intervention for persons with severe mental illness. *Psychological Services*, 3, 202-224. doi: 10.1037/1541-1559.4.3.202
- 107 Strassnig, M., & **Ganguli, R\***. (2007). Weight loss interventions for patients with schizophrenia. *Clinical Schizophrenia and Related Psychoses*, 1, 43-53.

- 108 Strassnig, M., Miewald, J., Keshavan, M., & **Ganguli, R\***. (2007). Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One year analysis. *Schizophrenia Research*, 93, 90-98. PMID 17478082
- 109 Amiel, J.M, Mangurian, C.V., **Ganguli, R.**, & Newcomer, J.W. (2008). Addressing cardiometabolic risk during treatment with antipsychotic medications. *Current Opinion in Psychiatry*, 21(6), 613-618. doi: 10.1097/YCO.0b013e328314b74b 00001504-200811000-00016 [pii] PMID 18852570
- 110 Coley, K.C., Fabian, T.J., Kim, E., Ammerman, D.K., Scipio, T.M., Saul, M.I. **Ganguli, R.** (2008). Predictors of aripiprazole treatment continuation in hospitalized patients. *Journal of Clinical Psychiatry*, 69, Suppl 6:1393-1397. doi: eJ08M04205 [pii] PMID 19012819
- 111 Everett, A., Mahler, J., Biblin, J., **Ganguli, R.**, & Mauer, B. (2008). Improving the health of mental health consumers: Effective policies and practices. *International Journal of Mental Health*, 37(2), 8-48.
- 112 **Ganguli, R.**, Brar, J.S., Jaspreet. S., Mahmoud, R., Berry, S.A., & Pandina, G.J. (2008). Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study. *BMC Medicine*, 6, 17. PMID 18590519.
- 113 **Ganguli, R.** (2009). Importance of metabolic syndrome for South Asians. *Asian Journal of Psychiatry*, 2(3), 93-94. doi: 10.1016/j.ajp.2009.08.00
- 114 **Ganguli, R.**, Cohn, T., & Faulkner, G. (2009). Behavioral treatments for weight management in schizophrenia. In J.M. Meyer & H.A. Nasrallah (Eds.), *Medical Illness and Schizophrenia*, 2nd Ed. Washington DC: American Psychiatric Press, Inc.
- 115 Rotondi, A.J., Anderson, C.M., Haas, G.L., Back, S.M., Spring, M.B., **Ganguli, R.**, Newhill, C., Rosenstock, J. (2010). Web-based psychoeducational intervention for persons with schizophrenia and their supporters: One-year outcomes. *Psychiatric Services*, 61(11), 1099-1105.
- 116 **Ganguli, R.**, Strassnig, M. (2011). Prevention of metabolic syndrome in serious mental illness. *Psychiatric Clinics of North America*, 34(1), 109-125. PMID 21333843.
- 117 Strassnig, M., Brar, J.S., **Gangul, R.** (2011). Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. *Schizophrenia Research*, 126(103):103-9. Epub 2010 Dec 13. PMID 21146958.
- 118 **Ganguli, R.**, Brar J.S., Garbut, R., Chang, C.C., Basu, R. (2011). Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. *Clinical Schizophrenia and Related Psychoses*, 5(2):75-9. PMID 21693430.
- 119 **Ganguli, R.**, (2011). Comorbidities of obesity in serious mental illness. *Psychiatric Annals*. 41:10, 469-472.
- 120 **Ganguli, R.**, Basu, R., Brar, J., Chang, C., & Garbut, R. (2011). Changes in weight and other metabolic indicators, in persons with schizophrenia, following a switch to aripiprazole. *Clinical Schizophrenia & Related Psychoses*, 5, 75-79. PMID 21693430

- 121 Kidd, S.A., Kaur Bajwa, J., McKenzie, K.J., **Ganguli, R.**, & Haji Khamneh, B. (2012). Cognitive remediation for individuals with psychosis in a supported education setting: A pilot study. *Rehabilitation Research and Practice*, 1-5. PMID 22666598
- 122 Strassing, M., Awerbuck, J., & **Ganguli, R.** (2012). Diabetes resolution following a discontinuation of a second-generation antipsychotic: Three cases. *Clinical Schizophrenia & Related Psychoses*.
- 123 Strassing, M., Brar, J.S., & **Ganguli, R\***. (2012) Health-related quality of life, adiposity, and sedentary behavior in patients with early schizophrenia: Preliminary study. *Diabetes, Metabolic Syndrome, and Obesity: Targets and Therapy*. 5:389-94. PMID: 23152691
- 124 Janney C.A., **R Ganguli**, C.R. Richardson, RG Holleman, G Tong, JA Cauley, AM Kriska. Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders. *Schizophrenia Research*. 2013:145:63-68.
- 125 Gorczynski P, Patel H, **Ganguli R.** Adherence to diabetes medication in individuals with schizophrenia. *Clin Schizophr Relat Psychoses*. 2014 Feb 4:1-31. [Epub ahead of print] PMID: 24496045
- 126 Kidd SA, Herman Y, Barbic S, **Ganguli R**, George TP, Hassan S, McKenzie K, Maples N, Velligan D. Testing a modification of cognitive adaptation training: streamlining the model for broader implementation. *Schizophr Res*. 2014 156(1):46-50. doi: 10.1016/j.schres.2014.03.026. Epub 2014 Apr 29. PMID: 24794880

### PUBLISHED ABSTRACTS

- 1 **Ganguli, R.**, & Rabin, B.S. (1989). Antibrain and generalized autoimmunity in a subgroup of RDC schizophrenics. *Schizophrenia Research*, 2, 150.
- 2 Keshavan, M.S., Brar, J.S., **Ganguli, R.**, Jarrett, D., Chaudhry, H.R., & Campbell, K. (1989). Dexamethasone nonsuppression and CT Scan changes in schizophrenia. *Biological Psychiatry*, 25, 39A.
- 3 Keshavan, M.S., Reynolds, C., Brar, J., Houck, P., Campbell, K., **Ganguli, R.**, & McEvoy, J. (1989). Pre-treatment sleep EEG parameters and prediction of response to haloperidol in schizophrenia. *Biological Psychiatry*, 25, 182A.
- 4 Keshavan, M.S., Reynolds, C., Brar, J., Houck, P, Campbell, K., **Ganguli, R.**, & McEvoy, J. (1989). Sleep EEG changes in schizophrenia during haloperidol treatment. *Biological Psychiatry*, 25, 181A.
- 5 Chengappa, K.N.R., Carpenter, A.B., Keshavan, M.S., Yang, Z.W., Kelly, R.H., Rabin, B.S., & **Ganguli, R.** (1991). Cardiolipin antibodies in a subgroup of medicated and never-medicated schizophrenic patients. *Biological Psychiatry*, 29, 651S.
- 6 **Ganguli, R.**, Chengappa, R., Yang, Z., Kelly, R.H., & Rabin, B.S. (1991). Clinical and immunologic correlates of antibrain antibodies in schizophrenic patients. *Biological Psychiatry*, 29, 71A.
- 7 **Ganguli, R.**, McAllister, C.G., Rabin, B.S., Solomon, W., Brar, J.S., & Rehn, T. (1991). Alterations in interleukins and in T-lymphocyte subsets in a subgroup of schizophrenics. *Biological Psychiatry*, 29, 109A.

- 8 McAllister, C.G., Rabin, B.S., & **Ganguli, R.** (1991). Autoimmune aspects of schizophrenia. *Biological Psychiatry*, 29, 36S.
- 9 Nimgaonkar, V.L., Brar, J.S., Solomon, W.K., Rabin, B.S., & **Ganguli, R.** (1991). Association between immune parameters and negative symptoms in schizophrenia. *Biological Psychiatry*, 29, 71A.
- 10 Torrey, E.F., Rapaport, M.H., **Ganguli, R.**, Honigam, A.M., Paul, S.M., McAllister, C.G. (...) Gottesman, I.I. (1991). Immunologic and virologic aspects of identical twins with schizophrenia. *Biological Psychiatry*, 29, 37S.
- 11 Chengappa, K.N.R., **Ganguli, R.**, Carpenter, A.B., Yang, Z.W., Brar, J.S. & Rabin, B.S. (1992). Handedness and autoantibodies in schizophrenic and control subjects. *Biological Psychiatry*, 31, 208A.
- 12 **Ganguli, R.**, Rabin, B.S., Chengappa, K.N.R., Nimgaonkar, V.L., McAllister, C.G., Yang, Z.W., & Brar, J.S. (1992). Autoimmune phenomena in schizophrenic patients. *Schizophrenia Research*, 6, 140-141.
- 13 Yang, Z.W., Chengappa, K.N.R., Shurin, G.V., Rabin, B.S., & **Ganguli, R.** (1992). Decrease in PHA-stimulated IL-2 production (ELISA) in schizophrenic patients is correlated to their clinical states. *Biological Psychiatry*, 31, 207A.
- 14 Chengappa, K.N.R., Nimgaonkar, V.L., Bachert, C., Yang, Z.W., Hammill, E., Brar, J.S. **Ganguli R.** (1993). An association between obstetric complications and autoantibodies in schizophrenia. *Schizophrenia Research*, 9, 216.
- 15 Chengappa, K.N.R., Shurin, G., Yang, Z.W., **Ganguli, R.**, & Rabin, B.S. (1993). The association of handedness (right or left) with immune function in healthy humans. *Research Perspectives in Psychoneuroimmunology IV*, Colorado.
- 16 Chengappa, K.N.R., Yang, Z.W., Shurin, G., Farooqui, S.M., Rabin, B.S., & **Ganguli, R.** (1993). Antibody reactivity to a D-2 receptor peptide in neuroleptic drug naive schizophrenic patients and normal controls. *Biological Psychiatry*, 33, 97A.
- 17 **Ganguli, R.**, Brar, J.S., Yang, Z.W., Shurin, G., & Rabin, B.S. (1993). T-lymphocyte subsets in schizophrenia and normal controls. (1993). *Biological Psychiatry*, 33, 100A.
- 18 **Ganguli, R.**, & Rabin, B.S. (1993). CD5 + B lymphocytes in schizophrenic patients and healthy controls. *Biological Psychiatry*, 33, 100a.
- 19 **Ganguli, R.**, Rabin, B.S., Chengappa, K.N.R., Yang, Z.W., Nimgaonkar, V.L., Brar, J.S., Solomon, W. (1993). Evidence for an autoimmune pathogenesis in a subgroup of schizophrenic patients. *Schizophrenia Research*, 9, 220.
- 20 **Ganguli, R.**, Sagawa, Y., Brar, J.S., Yang, Z.W., Chengappa, K.N.R., Shurin, G., & Rabin, B.S. (1993). Effect of routine everyday stress on interleukins. *Biological Psychiatry*, 33, 150A.
- 21 **Ganguli, R.**, Yang, Z.W., Chengappa, K.N.R., Shurin, G., & Rabin, B.S. (1993). Increased serum IL-6 concentration in schizophrenia. *Biological Psychiatry*, 33, 100A.

- 22 Nimgaonkar, V.L., **Ganguli, R.**, Rudert, W., Vavassori, C., Rabin, B.S., & Trucco, M. (1993). A negative association of schizophrenia with an allele of the HLA DQB1 gene among African-Americans. *Schizophrenia Research*, 9, 121.
- 23 Tanner, T.B., **Ganguli, R.**, Kubacka, R., Mulsant, B., & Gitlow, S. (1993). Medication education using a multimedia computer: A clinical trial. *Schizophrenia Research*, 9, 260.
- 24 **Ganguli, R.**, Brar, J.S., Damaraju, C.V., Sperner-Unterweger, B., Yang, Z.W., & Rabin, B.S. (1994). Negative symptoms in immunologically abnormal clusters of schizophrenics. *Biological Psychiatry*, 35(9), 726.
- 25 **Ganguli, R.**, Brar, J.S., DeLeo, M., Allen, M., & Sarma, R. (1994). Clozapine treatment in a community mental health setting: Effects on rehospitalization, positive, and negative symptoms. *Schizophrenia Research*, 11, 104.
- 26 **Ganguli, R.**, Brar, J.S., DeLeo, M., Allen, M., & Sarma, R. (1994). Reduced hospitalization with clozapine in a community mental health setting. *Biological Psychiatry*, 35(9), 742.
- 27 **Ganguli, R.**, Brar, J.S., Gubbi, A.V., Yang, Z.W., Chengappa, K.N.R., & Rabin, B.S. (1994). A longitudinal study of clinical and immune measures in schizophrenia. *Biological Psychiatry*, 35(9), 725.
- 28 **Ganguli, R.**, Mintun, M.A., Becker, J.T., Brar, J.S., Diehl, D.J., DeLeo, M. (...) Martidis, A. (1994). Effects of cognitive and physiological stimulation on regional cerebral blood flow in schizophrenics and normal controls: An <sup>15</sup>O PET study. *Schizophrenia Research* 11, 166.
- 29 **Ganguli, R.**, Mintun, M.A., Becker, J.T., Brar, J.S., Diehl, D., DeLeo, M. (...) Martidis, A. (1994). rCBF (<sup>15</sup>O PET) during cognitive and physiological stimulation in schizophrenics. *Biological Psychiatry*, 35(9), 621.
- 30 **Ganguli, R.**, Yang, Z.W., Chengappa, K.N.R, Brar, J.S., Shurin, G., & Rabin, B.S. (1994). Decreased mitogen-stimulated IL-2 production in first episode drug-naïve schizophrenic patients. *Schizophrenia Research* 11, 128.
- 31 **Ganguli, R.**, Yang, Z.W., Chengappa, K.N.R., Brar, J.S., Shurin, G., & Rabin, B.S. (1994). Decreased PHA stimulated IL-2 production in drug-naïve schizophrenics. *Biological Psychiatry*, 35(9), 708.
- 32 Nimgaonkar, V.L., Zhang, X.R., Caldwell, J.G., **Ganguli, R.**, & Chakravarti, A. (1994). Association studies in schizophrenia using dopamine D3 receptor gene polymorphism. *Schizophrenia Research*, 11, 145.
- 33 Nimgaonkar, V.L., Zhang, X.R., Caldwell, J.G., **Ganguli, R.**, & Chakravarti, A. (1994). Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: Probable effects of family history of schizophrenia? *American Journal of Medical Genetics*, 48(4), 214-217.
- 34 **Ganguli, R.**, Mintun, M., Carter, C., Sarma, R., Brar, J.S., Nichols, T., Benington, E. (1995). The functional neuroanatomy of memory in schizophrenia: An O<sup>15</sup>H<sub>2</sub>O PET study during supraspan memory performance. *Schizophrenia Research*, 15(1,2) 82.

- 35 Nimgaonkar, V.L., Zhang, X.R., Brar, J., DeLeo, M., Hogge, W., **Ganguli, R.**, & Chakravarti, A. (1995). Association between the dopamine D3 receptor gene locus and liability to schizophrenia, as well as its age of onset. *Schizophrenia Research*, 15(1,2) 45.
- 36 Schooler, N., Kane, J., Marder, S., Baker, R., Safferman, A., Wirshing, W., Ames, D., **Ganguli, R.**, Borenstein, M. (1995). Efficacy of clozapine vs haloperidol in a long term clinical trial: Preliminary findings. *Schizophrenia Research*, 15(1,2), 165.
- 37 Cohen, J.D., **Ganguli, R.**, Carter, C., Brar, J., Nichols, T., DeLeo, M., & Mintun, M. (1995). Hypofrontality and working memory dysfunction in schizophrenia. *Biological Psychiatry*, 37(9), 143.
- 38 Barch, D.M., Cohen, J.D., Servan-Schreiber, D., & **Ganguli, R.** (1995). The stability and interrelationships of CPT-AX and Stroop performance in schizophrenia. *Biological Psychiatry*, 37(9), 147.
- 39 Ward, S., Weston, N., Brar, J.S., DeLeo, M., **Ganguli, R.**, & Nimgaonkar, V.L. (1995). Reduced fertility in schizophrenia: Here to stay? *Biological Psychiatry*, 37(9), 163.
- 40 Ames, D., Wirshing, W.C., Kane, J., Schooler, N., Marder, S.R., Baker, R., Safferman, A., **Ganguli, R.** (...) Borenstein, M. (1995). Efficacy of Clozapine vs. Haloperidol in a long-term clinical trial: Preliminary results. *Biological Psychiatry*, 37(9). 242.
- 41 Kane, J.M., Schooler, N.R., Marder, S., Wirshing, W., Ames, D., Umbricht, D (...) **Ganguli, R.** (1996). Efficacy of clozapine versus haloperidol in a long-term clinical trial. *Schizophrenia Research*, 18(2), 3.
- 42 Lake, M.B., **Ganguli, R.**, Kuhn, B., & Gubbi, A. (1996). Weight gain and antipsychotics in schizophrenia. *Schizophrenia Research*, 18(2), 3.
- 43 **Ganguli, R.**, Rabin, B.S., Brar, J.S., & Gubbi, A.V. (1996). Relapse and changes in cytokine and antibody production in schizophrenia. *Schizophrenia Research*, 18(2), 3.
- 44 Richards, S.S., Sweet, R.A., & **Ganguli, R.** (1996). Clozapine: Acute and maintenance treatment in late-life psychoses. *The American Journal of Geriatric Psychiatry*, 4(4), 377-378.
- 45 Brar, J.S., & **Ganguli, R.** (1997). The effect of risperidone on the indications for clozapine. *Biological Psychiatry*, 41(7S), 75, 1997.
- 46 Brar JS, Chengappa KNR, Sandman AR, Kreinbrook SB, Sheth SA, & **Ganguli R.** (1997). Effect of clozapine on negative symptoms in schizophrenic patients with minimal positive symptoms. *Biological Psychiatry*, 41(7S), 244.
- 47 Sanders, R.D., Forman, S.D., Pierri, J., Jampala, V., Keshavan, M.S., **Ganguli, R.**, & van Kammen, D.P. (1997). The neuroleptic examination and negative symptoms in schizophrenia. *Biological Psychiatry*, 41(7S), 276.
- 48 **Ganguli, R.**, Brar, J.S., Kathiresan, S.M., Vemulapalli, H.K., Fleischer, A., & Onorato, M. (1997). Memory task performance in patients with schizophrenia and matched healthy controls. *Biological Psychiatry*, 41(7S), 291.



- 49 **Ganguli, R.**, Brar, J.S., Kathiresan, S.M., Vemulapalli, H.K., Fleischer, A., & Onorato, M. (1997). Effects of cortisol infusion on cognitive functions in schizophrenic patients and healthy controls. *Biological Psychiatry*, 41(7S), 292.
- 50 **Ganguli, R.**, Brar, J.S., Vemulapalli, H.K., & Nimgaonkar, V.L. (1997). Autoimmune diseases in first degree relatives of schizophrenic and control subjects. *Biological Psychiatry*, 41(7S), 394.
- 51 **Ganguli, R.**, & Brar, J.S. (1997). Indications for clozapine before and after the introduction of risperidone. *Psychopharmacology Bulletin*, 33(3), 526.
- 52 **Ganguli, R.** & Brar, J.S. (1998). The effects of risperidone and olanzapine on the indications for clozapine. *Psychopharmacology Bulletin*, 34(1), 83-87.
- 53 Levin, H., **Ganguli, R.**, Brar, J.S., Mehta, N., & Habibi, S. (1998). Obsessive compulsive symptoms in clozapine treated patients. *Biological Psychiatry*, 43(1S), 158.
- 54 **Ganguli, R.**, Brar, J.S., & Ayrton, Z. (1998). Weight gain in patients treated with risperidone and olanzapine. *Biological Psychiatry*, 43(1S), 388.
- 55 **Ganguli, R.**, Brar, J.S., & Chang, J. (2008). Effect of atomoxetine on negative symptoms of schizophrenia: A randomized double-blind placebo-controlled clinical trial. *Schizophrenia Research*, 102(1-3, Suppl. 2), 254.
- 56 **Ganguli, R.**, Brar J.S. (2011). Weight reduction in schizophrenia by lifestyle change: a randomized controlled clinical trial. *Canadian Journal of Diabetes*, 35:153.
- 57 Hassan, S., **Ganguli, R.**, Flett, G.L., Hewitt, P.L. (2012). Towards a phenomenological understanding of psychosis: Trait perfectionism in persons with psychotic illnesses. *Schizophrenia Research*, 136(Suppl 1), 136.
- 58 Hassan, S., **Ganguli, R.**, Flett, G.L., & Hewitt, P.L. (2012). Trait perfectionism and perfectionistic self-presentation in early psychosis. *Early Intervention in Psychiatry*, 6(Suppl 1), 58.
- 59 **Ganguli, R.**, & Janney, C.A. (2013). Physical activity in community-dwelling persons with schizophrenia. *Canadian Journal of Diabetes*, 37( Suppl 2), S242.
- 60 **Ganguli, R.**, Jenkins, T., & McKinnon, K. (2013). Weight loss in individuals with diabetes and psychosis: An intervention for community residential settings. *Biological Psychiatry*, 73(Suppl 2), 319S.
- 61 **Ganguli, R.**, Jenkins, T., & McKinnon, K. Bahmani, M (2013). Weight Loss Intervention for Individuals with Diabetes and Serious Mental Illness: a Pragmatic Experiment in Community Settings. *Canadian Journal of Diabetes*, 37(6) December 2013

**INVITED PRESENTATIONS  
(only listing presentations since 2008)**

- “Behavioral Strategies for weight management in people with severe and persistent mental disorders”. Diabetes & Mental Illness: An Holistic Approach to Healing Mind & Body; Diabetes Prevention Program in Schizophrenia, McMaster University, Hamilton, Ontario, April 23, 2008.
- “Electronic documentation for psychiatrists”. Centre for Addiction and Mental Health; Toronto, Ontario, June 4, 2008.
- “Educational and behavioral interventions for weight loss”. Obesity Reduction and Prevention Strategies for Individuals with Serious Mental Illness Conference; National Association of State Mental Health Program Directors, New York, New York, September 13, 2008.
- “Atmozetine effects on negative symptoms in schizophrenia: a randomized clinical trial”. International Congress on Schizophrenia Research; San Diego, California, March 31- April 2, 2009.
- “Efficacy of maintenance treatment in sustaining weight loss: a randomized controlled clinical trial”. American Psychiatric Association Annual Meeting; San Francisco, California, May 16-21, 2009.
- “Obesity and the metabolic syndrome with special reference to South Asians”. Texas Medical Association Conference; Houston, Texas, June 18-21, 2009.
- “Using evidence to provide safer care in mental health”. Mental Health & Patient Safety: Broadening our Understanding, Building the Momentum; Ontario Mental Health Association in partnership with the Canadian Patient Safety Institute; Toronto, Ontario, September 17-18, 2009.
- “Reducing the risk of heart disease and diabetes in serious mental illness”. Plenary session. New York State Office of Minority Health Annual Nursing Conference; Ellenville, New York, November 5-7, 2009.
- “Co-morbid cardiovascular.” Panel Discussant on Addictions and Mental Health. Health Achieve Conference; Toronto, Ontario, November 16-18, 2011.
- “Co-morbid medical disorders in psychoses” symposium. The Inaugural Indian Global Psychiatric Initiative 2010; Jaipur, India, January 15-16, 2010.
- “A clinical trial for weight reduction: lifestyle interventions in routine clinical care. American Psychiatric Association Annual Meeting; New Orleans, Louisiana, May 22-26, 2010.
- “Efficacy of behavioral treatment for weight loss in schizophrenia as compared to active controls and usual care”. World Psychiatric Association International Congress; Beijing, China, September 1-5, 2010.
- “Schizophrenia: special reference to persons of South Asian descent”. Canadian Psychiatric Association 61<sup>st</sup> Annual Conference; Toronto, Ontario, September 23-26, 2010.
- “Treating and preventing metabolic problems in persons with schizophrenia”. Psychiatry and Behavioral Sciences Grand Rounds, University of Texas Medical Branch; Houston, Texas, September 29, 2010.
- “Treatment of obesity and other metabolic abnormalities in persons with serious mental illnesses”. International Conference on Schizophrenia (IconS) IV of SCARF 2010; Chennai, India, October 22-24, 2010.

“Lifestyle interventions to reduce the risk of cardiovascular disease in serious mental illness”. Annual National Conference of Indian Psychiatric Society; New Delhi, India, January 16-19, 2011.

“Managing co-morbidity south asian perspective”. The Indian Global Psychiatric Initiative 2011; New Delhi, India, January 14-15, 2011.

“Internal and external barriers to accessing treatment for mental health issues in the South Asian community”. 2<sup>nd</sup> Annual Health Mela: A Prescription for Healthy Living. The Ripple Effect Wellness Organization; Brampton, Ontario, March 26, 2011.

“Weight reduction in schizophrenia, by lifestyle change: a randomized clinical trial”. 2<sup>nd</sup> National Obesity Summit; Montreal, Quebec, April 28 - May 1, 2011.

“Reducing the risk of cardiovascular disease and diabetes in serious mental illness”. Grand Rounds, Douglas and McGill University; Montreal, Quebec, April 27, 2011.

“Lifestyle treatments to reduce adverse weight and metabolic effects”. Adipogenic and Metabolic Effects of Antipsychotic Drugs Conference; Newark, New Jersey, July 11-12, 2011.

Preventing and treating metabolic syndrome in serious mental illness. Annual meeting of the American Psychiatric Association in Canada, April 17, 2014

## TEACHING

### CURRENT

#### A. LECTURES AND SEMINARS:

##### 1<sup>st</sup> & 2<sup>nd</sup> Year Psychiatric Residents:

###### “Administrative Psychiatry Case Conference”

This is a year-long monthly seminar at which each of the first year residents presents a case or case series in which administrative issues are prominent in the management of the clinical situation. Examples include civil commitment, seclusion and restraint, and managed care denial. Depending on the topic being discussed, members of the administration or legal department are asked to attend the case conference.

##### 2<sup>nd</sup> Year Psychiatric Residents:

###### “Schizophrenia & Psychotic Disorders”

Co-led with Ravinder Reddy, M.D. This is a didactic program in schizophrenia consisting of four 1 hour lectures.

**3<sup>rd</sup> Year Psychiatric Residents:****“Introduction to the Psychiatric Literature”**

This 18 session course is directed primarily at psychiatric residents in their third year of training, but residents from other years and some faculty also attend sporadically. The goal of this course is for residents to learn to distinguish good from bad evidence in the published literature. The format is for each of the residents to choose (with guidance) an article from a good peer-reviewed journal and to work on understanding the validity and robustness of the conclusions as presented by the authors. The analysis is then presented by the resident to the whole class. Over the course clinical trials covering efficacy, effectiveness, and harm are covered as well as studies of diagnostic tests, epidemiologic and economic analyses, and reviews and metaanalyses. One interactive session is conducted in the computer lab and is devoted to understanding effective search strategies for online databases.

**“Schizophrenia and Chronic Mental Disorders”**

Two 1 hour lectures, as part of a year-long course.

**2<sup>nd</sup> Year Medical Students:****“Psychosocial Consequences of Psychotic Illnesses”**

This 3 hour course is co-lead by a member of the National Alliance for the Mentally Ill. It is aimed at making medical students aware of the disabling nature of severe mental disorders as well as to introduce them to concept in psychiatric rehabilitation. The role of stigma in worsening social disability is also emphasized

**School of Nursing, Nurse Practitioner Program:****“Neuroscience and Mental Health”** (3 hour lecture)

This is a lecture/workshop for nurse practitioner/clinical nurse specialists on the biological basis of psychiatric disorders.

**B. RESEARCH MENTORING (since 1979)**

<b>Name of Trainee</b>	<b>Pre/Post Doctoral Trainee</b>	<b>Training Period</b>	<b>Current Degree</b>	<b>Research Project Title During Training with Dr. Ganguli</b>
Marilyn Davies	Pre	1979-1985	Ph.D.	Adjustment and treatment of community living schizophrenic patients (research for her PhD, School of Nursing, University of Pittsburgh) PhD granted in 1985
Michael Silver	Pre	1990-1991	Ph.D.	Autoimmune phenomena in schizophrenia: brain protein histochemistry (research for PhD, Department of Biology, University of Pittsburgh)
K.N.R. Chengappa	Post	1990-1992	M.D.	Autoimmune phenomena in schizophrenia: anti-cardiolipin antibodies (NIMH Research Fellowship)

Michael Pezzone	Pre	1991-1994	M.D., PhD	Characterization of the pathways mediating stress-induced immune alterations in the rat and humans (research for PhD, School of Medicine, University of Pittsburgh)
Archana Dube	Pre	1997-2000	Ph.D.	Models for predicting readmission of schizophrenia individuals (research for PhD, Graduate School of Public Health, University of Pittsburgh)
Kathy Sekula	Pre	1996-1997	PhD	Self-reported dimensions of mood state and plasma ACTH/cortisol levels in major depression (research for PhD, School of Nursing, University of Pittsburgh)
Shitij Kapur	Post	1992-1993	M.D.	Compliance in schizophrenia. (Research track resident, School of Medicine, University of Pittsburgh)
David Madoff	Post	1993	M.D.	PET studies in schizophrenia. (Research fellow, Department of Radiology, School of Medicine, University of Pittsburgh).
Jaspreet Brar	Post	1992-1994	M.D., MPH	Characteristics of first episode studies in schizophrenia (Research for MPH degree, Graduate School of Public Health, University of Pittsburgh)
Jennifer Pasternack	Post	1998-1999	MD	Effects of case management on the utilization of acute psychiatric services, by individuals with SPMI (research track resident, School of Medicine, University of Pittsburgh)
Vishwajit L Nimgaonkar	Post	1992-1994	MD, PhD	Immunogenetics and schizophrenia (Post-Doctoral fellow, School of Medicine, University of Pittsburgh)
John McLennan	Post	1995-1996	MD	Health teaching and practices related to family planning in women suffering from schizophrenia (research track resident, School of Medicine, University of Pittsburgh)
Mary Beth Lake	Post	1995-1997	MD	Weight gain related to antipsychotic treatment (research track resident, School of Medicine, University of Pittsburgh)
Stephanie Richards	Post	1996-1997	MD	Use of antipsychotics in the elderly (research track resident, School of Medicine, University of Pittsburgh , co-mentor Robert Sweet, MD)
Martin Strassnig	Post	2001-2011	MD	Nutritional intake in community-dwelling individuals with schizophrenia (research fellow and research track resident, School of Medicine, University of Pittsburgh)
Avinash Hosanagar	Post	2006-2008	MD	Metabolic syndrome and other indices of cardiovascular disease risk in schizophrenia compared to bipolar disorder (research track resident, School of Medicine, University of Pittsburgh)

Carol A. Janey	Pre	2008-present	PhD	Physical activity in overweight and obese adults with schizophrenia and schizoaffective disorders. (research for PhD in Epidemiology, Graduate School of Public Health, University of Pittsburgh)– PhD granted in March 2012
Sabrina Hassan	Pre	2011-present	MS	Perfectionism in psychotic illness – (research for PhD in Clinical Psychology, York University)
Yulia Knyahnytska	Pre	2012-present	MS	Qualitative studies in adherence behaviour in persons with serious mental illness and diabetes (research for PhD in Public Health [Health and Behavioral Sciences], Dalla Lana School of Public Health, University of Toronto)
Hiren Patel	Pre	2012-present	BA	Role of exercise and health status in individuals with mental illness and type-2 diabetes mellitus (research for MSc at Institute of medical Sciences, University of Toronto)
Paul F. Gorczyński	Post	2012-present	PhD	Lifestyle Interventions (LI) for Diabetes Management in Psychotic Illness.

**PAST**

- 1974-75 Taught courses in General and Forensic Psychiatry for medical students, Christian Medical College, Vellore, India.
- 1976 2nd year Neurosciences and 3rd year Psychiatry courses for undergraduate medical students, Memorial University, Newfoundland.
- 1977 3rd year Psychiatry for undergraduate students, Memorial University of Newfoundland.
- 1977 “Drugs used in Psychiatry” taught at courses for Public Health Nurses in St. John's Newfoundland.
- 1978-1991 "Mental Status Examination": taught every six weeks to 3rd year medical students.
- 1979-1992 "Schizophrenia": taught to occupational therapy students, once a year in their "Psychopathology" course in the School of Health Related Professions. (3 hours.)
- 1979 3rd year medical students, didactic program in psychiatry: "The Mental Status Exam" and "Management of Psychiatric Emergencies."
- 1979-81 Course Coordinator: "General Psychiatry II".
- 1980-81 Psychology Internship program: Psychopharmacology."
- 1981-82 3rd year medical students, didactic program in psychiatry: "The Mental Status Exam" and "Management of Psychiatric Emergencies."

- 1984 2nd year medical students: "The Neuropsychiatric Manifestations of Alcoholism."
- 1985-1987 2nd year residents in psychiatry - "Adult Psychopathology", "Paranoid Disorders."
- 1987-1988 Co-Coordinator of "Psychopharmacology" a series of lectures for 1st and 2nd year psychiatric residents (14 hours).
- 1986-1988 "Structured Psychiatric Interviews": taught to psychology interns as part of "Psychiatric Assessment Methods" course (2 hours).

### **OTHER RESEARCH RELATED ACTIVITIES:**

#### **Editorial Service - Reviewer for the following peer-reviewed journals:**

1. Archives of General Psychiatry
2. American Journal of Psychiatry
3. Journal of the American Medical Association
4. Schizophrenia Bulletin
5. Biological Psychiatry
6. Schizophrenia Research
7. Brain Behavior and Immunity
8. Clinical Psychology Review
9. Psychiatry Research
10. International Journal of Obesity

### **SERVICE**

#### **A. GRANT REVIEWING:**

Member, NIMH Data Safety Monitoring Board

Ad hoc reviewer, National Institute of Mental Health

Ad hoc reviewer, Veterans' Administration Merit Review

Ad hoc reviewer Medical Research Council of Canada

**B. COMMUNITY SERVICE:**

**Chair, Board of Directors, Village Family Health Team, Toronto, Canada.** 2011-present  
The Village Family Health Team is an interdisciplinary primary care service funded by the Province of Ontario Canada.

**Board of Directors, Vellore Christian Medical College Foundation, New York, NY.** 2010-present

**Allegheny County Mental Health/Mental Retardation Advisory Board,** 1999 – 2007 (President of the Board from 2000-2005)  
(This board serves to advise the Chief Executive of the county with regard to mental health and mental retardation services for the county's 1.5 million citizens)

Member, **Allegheny County Human Services Oversight Committee** 1999 - 2004  
(This committee oversees the operation of Allegheny County's Department of Human Services which includes mental health, drug & alcohol, mental retardation, aging, and child welfare services)

Member, **Community Care Behavioral Health (CCBH) - Care Management Committee** 1998 - 2008  
(CCBH is the non-profit HMO which is contracted to provide all behavioral health services to Allegheny County's residents who are on public assistance)

Member, **Executive Council, Pittsburgh Psychiatric Society** 1999 – 2001

Member **Board of Directors of the American Red Cross of SW Pennsylvania** 2005-2008

President **Board of Directors of Village Family Health Team**, Toronto, Ontario, Canada 2010-present

Member **Scientific Advisory Council, Schizophrenia Society of Ontario,** 2011

**C. PAST SERVICE:**

Chief Resident in Psychiatry, St. Claire's Mercy Hospital. St. John's Newfoundland. 1976-1977. Program Director, 8th Floor Inpatient Unit, WPIC 1979-1980.

Faculty of Psychology Internship, University of Pittsburgh, 1979-1981.

Course Coordinator, Residency Education Committee for General Psychiatry II, 1979-1981.

Interviewing Committee for Admissions, University of Pittsburgh, School of Medicine, 1979, 1980, 1981, 1982.

Chairman, Subcommittee on Exams in Psychiatry, for medical students, University of Pittsburgh, School of Medicine, 1979, 1980.

Member Academic Promotions Committee, Chairman, Subcommittee on Non-Tenure renewals. 1984-1986.

Chairman, WPIC Medical Audit Committee, 1985-1987.

Member, Unified Systems Committee



Member, Dean's Committee on Mayview State Hospital

Member, Mayview Research Committee

Member, Executive Committee of WPIC Medical Staff.

Member, WPIC Utilization Review Committee

Member UPMC Medical Executive Committee

Member Deans Committee for the VA